[{"id":"2304e211-cb24-49e4-804c-c1f372c07411","acronym":"ARTEMIDE-HCC01","url":"https://clinicaltrials.gov/study/NCT06921785","created_at":"2025-06-07T14:44:45.235Z","updated_at":"2025-06-07T14:44:45.235Z","phase":"Phase 3","brief_title":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","source_id_and_acronym":"NCT06921785 - ARTEMIDE-HCC01","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imjudo (tremelimumab-actl) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 1220","initiation":"Initiation: 05/06/2025","start_date":" 05/06/2025","primary_txt":" Primary completion: 03/16/2029","primary_completion_date":" 03/16/2029","study_txt":" Completion: 03/15/2030","study_completion_date":" 03/15/2030","last_update_posted":"2025-05-31"},{"id":"008c4fb4-f4aa-40c4-a175-3806ddd34919","acronym":"ARTEMIDELung04","url":"https://clinicaltrials.gov/study/NCT06868277","created_at":"2025-06-07T15:03:08.757Z","updated_at":"2025-06-07T15:03:08.757Z","phase":"Phase 3","brief_title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT06868277 - ARTEMIDELung04","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 830","initiation":"Initiation: 04/10/2025","start_date":" 04/10/2025","primary_txt":" Primary completion: 01/17/2030","primary_completion_date":" 01/17/2030","study_txt":" Completion: 12/02/2030","study_completion_date":" 12/02/2030","last_update_posted":"2025-05-14"},{"id":"ec39bba5-c725-4310-a7b9-db843f8fcd99","acronym":"AdvanTIG-206","url":"https://clinicaltrials.gov/study/NCT04948697","created_at":"2021-07-02T12:52:38.466Z","updated_at":"2025-02-25T12:28:13.406Z","phase":"Phase 2","brief_title":"A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC","source_id_and_acronym":"NCT04948697 - AdvanTIG-206","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)"],"overall_status":"Completed","enrollment":" Enrollment 94","initiation":"Initiation: 08/20/2021","start_date":" 08/20/2021","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2025-02-24"},{"id":"a672992d-19fb-49b7-9557-516b222cb23a","acronym":"ARTEMIDE-Lung03","url":"https://clinicaltrials.gov/study/NCT06627647","created_at":"2025-02-25T13:36:39.041Z","updated_at":"2025-02-25T13:36:39.041Z","phase":"Phase 3","brief_title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC","source_id_and_acronym":"NCT06627647 - ARTEMIDE-Lung03","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 878","initiation":"Initiation: 11/27/2024","start_date":" 11/27/2024","primary_txt":" Primary completion: 05/10/2029","primary_completion_date":" 05/10/2029","study_txt":" Completion: 03/25/2030","study_completion_date":" 03/25/2030","last_update_posted":"2025-02-21"},{"id":"9a2be334-2a03-47f4-bac6-d53ac52c474b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05286801","created_at":"2022-03-18T11:54:26.510Z","updated_at":"2025-02-25T14:08:43.679Z","phase":"Phase 1/2","brief_title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","source_id_and_acronym":"NCT05286801","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFA • SMARCB1","pipe":" | ","alterations":" SMARCA4 mutation","tags":["TNFA • SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-19"},{"id":"9d25a695-254b-48a3-8558-1b24c9498777","acronym":"ARTEMIDE-01","url":"https://clinicaltrials.gov/study/NCT04995523","created_at":"2021-08-09T14:53:19.305Z","updated_at":"2025-02-25T15:12:13.323Z","phase":"Phase 1/2","brief_title":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","source_id_and_acronym":"NCT04995523 - ARTEMIDE-01","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 08/18/2026","primary_completion_date":" 08/18/2026","study_txt":" Completion: 03/16/2028","study_completion_date":" 03/16/2028","last_update_posted":"2025-02-13"},{"id":"5140cf2b-ceba-4625-9ec1-ad9d0bbb9e1b","acronym":"KEYVIBE 007","url":"https://clinicaltrials.gov/study/NCT05226598","created_at":"2025-02-25T15:19:31.574Z","updated_at":"2025-02-25T15:19:31.574Z","phase":"Phase 3","brief_title":"Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)","source_id_and_acronym":"NCT05226598 - KEYVIBE 007","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 739","initiation":"Initiation: 03/24/2022","start_date":" 03/24/2022","primary_txt":" Primary completion: 09/24/2024","primary_completion_date":" 09/24/2024","study_txt":" Completion: 01/09/2026","study_completion_date":" 01/09/2026","last_update_posted":"2025-02-11"},{"id":"e4341e18-0636-4930-ba0b-0c9da6c26d3f","acronym":"DESTINY-BTC01","url":"https://clinicaltrials.gov/study/NCT06467357","created_at":"2025-02-25T15:45:41.147Z","updated_at":"2025-02-25T15:45:41.147Z","phase":"Phase 3","brief_title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","source_id_and_acronym":"NCT06467357 - DESTINY-BTC01","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 620","initiation":"Initiation: 08/12/2024","start_date":" 08/12/2024","primary_txt":" Primary completion: 06/12/2028","primary_completion_date":" 06/12/2028","study_txt":" Completion: 05/16/2029","study_completion_date":" 05/16/2029","last_update_posted":"2025-02-11"},{"id":"38d14a85-f7dd-4762-9bf5-4da0e8be0e8f","acronym":"KEYMAKER-U04 Substudy","url":"https://clinicaltrials.gov/study/NCT05845814","created_at":"2023-05-06T15:04:43.804Z","updated_at":"2025-02-25T15:28:00.798Z","phase":"Phase 1/2","brief_title":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","source_id_and_acronym":"NCT05845814 - KEYMAKER-U04 Substudy","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Padcev (enfortumab vedotin-ejfv) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 06/23/2023","start_date":" 06/23/2023","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2025-02-10"},{"id":"51e03560-3fbd-46cb-a1fe-077e9eea8d40","acronym":"","url":"https://clinicaltrials.gov/study/NCT05681039","created_at":"2023-01-11T14:59:21.452Z","updated_at":"2025-02-25T15:44:59.452Z","phase":"Phase 2","brief_title":"Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).","source_id_and_acronym":"NCT05681039","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • carboplatin • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/02/2023","start_date":" 06/02/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-02-10"},{"id":"d0347077-1070-49c3-a0e1-7799efd634bd","acronym":"SKYSCRAPER-05","url":"https://clinicaltrials.gov/study/NCT04832854","created_at":"2021-04-06T11:55:21.945Z","updated_at":"2025-02-25T15:19:05.163Z","phase":"Phase 2","brief_title":"A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04832854 - SKYSCRAPER-05","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • carboplatin • gemcitabine • paclitaxel • pemetrexed • tiragolumab (RG6058)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/23/2021","start_date":" 04/23/2021","primary_txt":" Primary completion: 03/05/2025","primary_completion_date":" 03/05/2025","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2025-02-10"},{"id":"5741b2e4-403a-47d5-b489-ab51fac66036","acronym":"","url":"https://clinicaltrials.gov/study/NCT05645692","created_at":"2022-12-09T14:57:54.227Z","updated_at":"2025-02-25T16:39:31.560Z","phase":"Phase 2","brief_title":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","source_id_and_acronym":"NCT05645692","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 204","initiation":"Initiation: 04/13/2023","start_date":" 04/13/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-02-06"},{"id":"b5311e32-e5a1-4a67-a74a-af139d0dfb7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04958811","created_at":"2021-07-12T15:53:06.793Z","updated_at":"2025-02-25T16:38:29.835Z","phase":"Phase 2","brief_title":"Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC","source_id_and_acronym":"NCT04958811","lead_sponsor":"Georgetown University","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK wild-type • ROS1 wild-type","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK wild-type • ROS1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/21/2021","start_date":" 12/21/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-06"},{"id":"6cdcc31a-0ce3-49ee-bdf9-1051ddeebebe","acronym":"TROPION-Lung10","url":"https://clinicaltrials.gov/study/NCT06357533","created_at":"2024-04-10T18:42:49.173Z","updated_at":"2025-02-25T16:55:47.733Z","phase":"Phase 3","brief_title":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations","source_id_and_acronym":"NCT06357533 - TROPION-Lung10","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1 • TACSTD2","pipe":" | ","alterations":" TROP2 positive","tags":["PD-L1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TROP2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 675","initiation":"Initiation: 04/11/2024","start_date":" 04/11/2024","primary_txt":" Primary completion: 04/24/2028","primary_completion_date":" 04/24/2028","study_txt":" Completion: 05/24/2030","study_completion_date":" 05/24/2030","last_update_posted":"2025-02-04"},{"id":"b72eb8f1-94d0-4f21-ae23-71349994cf41","acronym":"AFT-57","url":"https://clinicaltrials.gov/study/NCT05798663","created_at":"2023-04-04T16:04:15.011Z","updated_at":"2025-02-25T17:02:30.093Z","phase":"Phase 2","brief_title":"Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC","source_id_and_acronym":"NCT05798663 - AFT-57","lead_sponsor":"Alliance Foundation Trials, LLC.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 12/07/2023","start_date":" 12/07/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-03"},{"id":"b338379e-ef5a-43a2-a2ae-225d86a98ac0","acronym":"AdvanTIG-203","url":"https://clinicaltrials.gov/study/NCT04732494","created_at":"2021-02-01T16:58:08.345Z","updated_at":"2025-02-25T17:30:34.219Z","phase":"Phase 2","brief_title":"Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT04732494 - AdvanTIG-203","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)"],"overall_status":"Completed","enrollment":" Enrollment 125","initiation":"Initiation: 03/31/2021","start_date":" 03/31/2021","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 12/26/2023","study_completion_date":" 12/26/2023","last_update_posted":"2025-01-31"},{"id":"e1db77e0-90c7-4f64-afe7-e9f653e16ebf","acronym":"ARTEMIDE-Gastric01","url":"https://clinicaltrials.gov/study/NCT06764875","created_at":"2025-02-26T07:06:51.440Z","updated_at":"2025-02-26T07:06:51.440Z","phase":"Phase 3","brief_title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","source_id_and_acronym":"NCT06764875 - ARTEMIDE-Gastric01","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 840","initiation":"Initiation: 03/28/2025","start_date":" 03/28/2025","primary_txt":" Primary completion: 04/27/2029","primary_completion_date":" 04/27/2029","study_txt":" Completion: 12/09/2030","study_completion_date":" 12/09/2030","last_update_posted":"2025-01-09"},{"id":"d5cf9deb-5221-48da-8860-edd0ad9556de","acronym":"IMperator","url":"https://clinicaltrials.gov/study/NCT06331598","created_at":"2025-02-26T08:19:48.665Z","updated_at":"2025-02-26T08:19:48.665Z","phase":"Phase 2","brief_title":"A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)","source_id_and_acronym":"NCT06331598 - IMperator","lead_sponsor":"Hoffmann-La Roche","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2024","start_date":" 11/30/2024","primary_txt":" Primary completion: 10/20/2028","primary_completion_date":" 10/20/2028","study_txt":" Completion: 09/20/2029","study_completion_date":" 09/20/2029","last_update_posted":"2024-12-24"},{"id":"b5c67bd8-1ff6-480e-a8fd-8f1eefdac24b","acronym":"ARTEMIDE-Lung02","url":"https://clinicaltrials.gov/study/NCT06692738","created_at":"2025-02-26T08:58:21.285Z","updated_at":"2025-02-26T08:58:21.285Z","phase":"Phase 3","brief_title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT06692738 - ARTEMIDE-Lung02","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 880","initiation":"Initiation: 11/18/2024","start_date":" 11/18/2024","primary_txt":" Primary completion: 02/05/2029","primary_completion_date":" 02/05/2029","study_txt":" Completion: 10/08/2029","study_completion_date":" 10/08/2029","last_update_posted":"2024-12-11"},{"id":"50e95443-c92c-48dc-b638-e94294dd906a","acronym":"KEYNOTE-A72","url":"https://clinicaltrials.gov/study/NCT03260322","created_at":"2021-01-18T16:06:27.240Z","updated_at":"2025-02-25T16:06:46.737Z","phase":"Phase 1","brief_title":"A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT03260322 - KEYNOTE-A72","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ASP8374"],"overall_status":"Completed","enrollment":" Enrollment 169","initiation":"Initiation: 09/08/2017","start_date":" 09/08/2017","primary_txt":" Primary completion: 05/10/2022","primary_completion_date":" 05/10/2022","study_txt":" Completion: 05/10/2022","study_completion_date":" 05/10/2022","last_update_posted":"2024-11-13"},{"id":"69c870d6-f40e-4b1b-abc9-4c80e6cfc8ec","acronym":"KEYVIBE-006","url":"https://clinicaltrials.gov/study/NCT05298423","created_at":"2022-03-28T12:52:45.401Z","updated_at":"2024-07-02T16:34:25.855Z","phase":"Phase 3","brief_title":"Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)","source_id_and_acronym":"NCT05298423 - KEYVIBE-006","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • etoposide IV • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Recruiting","enrollment":" Enrollment 784","initiation":"Initiation: 05/03/2022","start_date":" 05/03/2022","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/04/2029","study_completion_date":" 09/04/2029","last_update_posted":"2024-06-14"},{"id":"c83f1ca5-f8ac-4ba6-b9aa-01738d1a4ab7","acronym":"KeyVibe-003","url":"https://clinicaltrials.gov/study/NCT04738487","created_at":"2021-02-04T18:58:44.596Z","updated_at":"2024-07-02T16:34:26.003Z","phase":"Phase 3","brief_title":"Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)","source_id_and_acronym":"NCT04738487 - KeyVibe-003","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • PD-L1 • ALK • ROS1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1 • ALK • ROS1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Recruiting","enrollment":" Enrollment 1246","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 04/21/2026","primary_completion_date":" 04/21/2026","study_txt":" Completion: 06/05/2028","study_completion_date":" 06/05/2028","last_update_posted":"2024-06-14"},{"id":"ac47ac70-8d3e-44cd-9e5c-4352a399115f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05459129","created_at":"2022-07-14T13:54:32.957Z","updated_at":"2024-07-02T16:34:26.668Z","phase":"Phase 1/2","brief_title":"A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)","source_id_and_acronym":"NCT05459129","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • paclitaxel • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 04/13/2023","start_date":" 04/13/2023","primary_txt":" Primary completion: 08/11/2024","primary_completion_date":" 08/11/2024","study_txt":" Completion: 08/11/2024","study_completion_date":" 08/11/2024","last_update_posted":"2024-06-12"},{"id":"e2d54c14-c32b-40ed-857b-e3c6d02e177f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05715281","created_at":"2023-02-08T18:00:05.180Z","updated_at":"2024-07-02T16:34:36.920Z","phase":"Phase 2","brief_title":"Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial","source_id_and_acronym":"NCT05715281","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCA4 mutation","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/26/2023","start_date":" 09/26/2023","primary_txt":" Primary completion: 10/15/2026","primary_completion_date":" 10/15/2026","study_txt":" Completion: 10/15/2026","study_completion_date":" 10/15/2026","last_update_posted":"2024-06-10"}]